Odronextamab

对Biotech而言，"单CDMO赌运气"模式或走向终结，双场地布局加速成为行业共识。诺和诺德接盘的原Catalent问题工厂，终遭客户弃用Guide View2026年8月，SMA领域创新药企Scholar Rock正式宣布弃用诺和诺德旗下布卢明顿工厂，将核心管线apitegromab的BLA申报资料中的该厂区彻底移除，完全转向备用工厂推进FDA审评。这起事件看似是药企更换外包供应商，实则是全球生物药外包行业极具标杆意义的案例：候选药物临床数据完整、无任何疗效与安全性问题，却在2025年9月因生产场地GMP缺陷首次遭遇CRL拒批；2026年3月重报后，场地同年4月复检仍不合格、8月被正式列为OAI（官方行动指示），企业最终主动弃厂。本次风波的核心涉事厂区，正是原康泰伦特（Catalent）美国印第安纳州布卢明顿无菌工厂。作为康泰伦特老牌核心无菌灌装基地，该厂区长期承接Biotech、大型药企的生物药商业化灌装订单，再生元、Incyte、Scholar Rock等多家企业的管线均在此落地生产。2024年底，诺和控股以165亿美元完成对康泰伦特整体私有化收购，这笔交易至今仍是全球CDMO行业史上金额最高的并购案；作为交易架构的一环，诺和诺德再斥资110亿美元，从诺和控股手中承接三家无菌灌装工厂。交易落地之初，市场视角大多聚焦于诺和诺德保障司美格鲁肽灌装产能的战略诉求，很少有人留意资产划分的潜在影响。交易完成后，康泰伦特作为诺和控股旗下独立子公司继续运营全球五十余座生产基地，而诺和诺德承接的三处资产中，恰恰是美国布卢明顿工厂长期存在GMP系统性缺陷。如今Scholar Rock被迫弃厂的结局，也让行业再度复盘：这场史上最大CDMO并购衍生出的资产拆分，是否一开始就已埋下了持续发酵的合规风险。合规连环暴雷，全球顶级药企也难"拯救"Guide View并购交易与资产拆分落地初期，市场普遍存在一轮乐观预期。市场普遍认为，诺和诺德作为全球顶级药企，依托其资源与体系，有能力逐步解决布卢明顿工厂的合规问题。媒体此前报道过该工厂的合规问题，诺和诺德正是在明知这些问题的前提下，选择亲自下场收购并推动整改；同时，这笔交易对司美格鲁肽灌装产能的释放，也被视为重大利好。但近一年半的整改结果，打破了当初的乐观想象。FDA检查记录显示，该厂的偏差处理能力长期不足——仅2021年10月至2023年10月间，该工厂就发生了约194起偏差事件，其中171起未能查明根本原因，意味着工厂的质量体系长期无法有效识别和解决问题。2025年，FDA对该厂区的现场检查出具了483观察表格，缺陷主要集中在无菌灌装线的污染控制、环境监测及CAPA有效性等核心领域，并将厂区正式列为OAI最高监管风险等级。诺和诺德持续投入大量资源优化工厂运营、补强质量体系。然而2026年4月FDA复检显示，此前长期存在的无菌管控漏洞、现场操作惯性、CAPA执行虚化问题仍未完全消除；2026年8月，FDA确认厂区依旧维持OAI分类，监管风险未能解除。持续的合规僵局，直接导致多家依赖该厂区的药企管线集体受挫：Scholar Rock：apitegromab于2025年9月首次收到CRL，2026年3月重报后因该厂再次OAI，最终弃厂转向备用工厂。再生元（Regeneron）：Eylea HD预充针剂型补充申请与双抗odronextamab先后遭遇审批阻滞，后者第二封CRL直接指向布卢明顿工厂的检查缺陷。Incyte：非小细胞肺癌药物Zynyz于2026年3月收到CRL，FDA明确指出"这是唯一问题——没有其他审批障碍"。一座问题厂区引发多款药物审评受阻，充分暴露了创新药单一CDMO绑定模式的风险。相似剧情还在持续上演。近日，放射性药物企业ITM披露，核心管线ITM-11收到FDA CRL。本次拒批同样不存在临床疗效与安全性争议，问题完全集中在CMC质量控制与第三方商业化生产设施层面。需要明确的是，ITM-11的涉事生产场地与本次爆雷的布卢明顿工厂无任何关联，是完全独立的另一宗行业案例。但两起前后相继的拒批事件形成互证，进一步说明行业共性风险：即便创新药临床数据优异、疗效安全性确凿，依然无法抵消外包生产端场地合规风险带来的监管不确定性。在当前日趋严苛的FDA监管体系下，Biotech过度依赖单一CDMO、单一生产场地的外包模式，正在持续放大管线审批风险，付出的合规与时间代价越来越高昂——比如ITM-11作为诺华Lutathera的潜在竞争者，能否在解决生产问题后顺利上市，不仅关乎其自身命运，也将影响其中国合作伙伴远大医药的核药布局节奏。给CDMO并购敲响警钟，也推动外包行业调整核心规则Guide View本次事件也在一定程度上修正了市场对CDMO资产并购的固有预期：资产交易可以快速完成设备、产能、场地的权属交割，但数十年积累的合规隐性负债、质量文化短板，无法随资产一并转移和清零。诺和诺德的整改困境，也让行业更清楚地认识到：CDMO厂区的核心价值，从来不止是产能与硬件，还包括长期沉淀的合规信用与体系执行力。布卢明顿工厂连环爆雷事件，或许正在推动全球生物药外包行业某些核心规则的调整。其一，Biotech的CMC供应链策略加速迭代。 过去多数临床后期创新企业，为控制成本、简化管线管理，普遍采用"单一核心CDMO"的绑定模式。而本次事件后，资本市场（遭遇CRL通常伴随股价大幅波动）与监管环境的变化，可能共同倒逼行业重新审视这一策略，临床III期及商业化阶段管线双生产场地布局，或加速成为更多企业的选择，单一厂区绑定的风险则被进一步放大。其二，药企CDMO并购尽调逻辑面临重构。诺和控股对Catalent的165亿美元并购，从其后续对工厂合规风险的处置节奏来看，并购尽调对厂区长期合规负债权重或有不足；另一种可能是，诺和诺德出于GLP-1灌装产能的战略优先级，在媒体已报道合规问题的前提下，选择容忍工厂的历史合规隐患并相信能够整改到位，才最终酿成如今持续发酵的后果。本次事件后，历史长期合规记录、历年检查缺陷、CAPA闭环有效性、厂区质量文化等隐性合规负债，很有可能成为行业并购尽调的核心优先级指标，CDMO资产并购或逐步进入"合规优先"的新阶段。最后，就行业发展而言，合规信用不足的产能将加速淘汰，竞争重心进一步转向合规质量体系。结语Guide View纵观整个行业发展史，资本可以收购产能、收购设备、收购成熟的外包资产，却无法在短期内同步重塑一座工厂沉淀数十年的合规基因与质量文化。Scholar Rock弃厂、诺和诺德近一年半整改未果的完整案例，不只是一次偶然的监管事故，更是全球生物药CDMO行业的一次深度合规警示：资本无法靠收购直接"买来"合规能力。在监管尺度持续收紧、行业风险显性化的当下，靠存量产能、历史红利、粗放管理生存的模式，正面临越来越大的挑战。长期来看，唯有体系完善、合规扎实、质量可控的产能，才能支撑创新药行业的持续发展。参考来源：[1] 盖德视界观察[2] Scholar Rock[3] ITM制作策划策划：May /  审核校对：Jeff撰写编辑：May /  封面图来源：网络免责声明：本文仅代表作者个人观点，参考文献如上，如对文中内容有不同意见，欢迎下方留言讨论。如需转载，请邮箱guideview@guidechem.com联系我们。

Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a candidate for spinal muscular atrophy. The Cambridge, Massachusetts-based biotech announced the move Friday, while assuring investors of the FDA’s target decision date of Sept. 30. The decision comes a year after problems at the legacy Catalent fill-finish facility in Bloomington, Indiana, triggered a complete response letter for Scholar Rock’s original application for apitegromab. The FDA slapped the facility with a Form 483 in July 2025, then escalated it to a warning letter in November. Since the original snub, Scholar Rock has refiled apitegromab in March 2026, listing two third-party fill-finish facilities, including the “Catalent Indiana LLC” site and another U.S.-based facility “producing numerous commercial products,” according to its announcement Friday. However, another inspection of the legacy Catalent site in April 2026 again led to a Form 483. When Scholar Rock CEO David Hallal hopped on the company’s second-quarter earnings call on Thursday, the FDA had not issued an official classification of the April 2026 inspection. At the time, Hallal touted his firm’s optionality, with two available facilities, whichever is found to be the fastest. That changed on Friday, when Novo alerted Scholar Rock that the agency had issued an “Official Action Indicated” (OAI) designation, which indicates serious violations requiring follow-up enforcement. “We view this as part of an ongoing process and remain focused on the work already underway to address the agency's observations, as the quality of the medicines we make remains a top priority,” a Novo spokesperson said of the OAI in a statement to Fierce Pharma. “Over the past year, Novo Nordisk has invested significant resources in improving operations and enhancing quality systems at the facility,” the spokesperson added. “Site Bloomington remains an important part of Novo Nordisk's operations, and we will continue working collaboratively and transparently with the FDA as we move forward.” Still, Scholar Rock is shifting all its apitegromab application to the second facility. “[T]he FDA review of the facility is advancing, robust supply for commercialization is ready and awaiting packaging and labeling at a third-party site, and importantly, the facility has demonstrated a strong track record of compliance, including recent successful FDA and EMA inspections,” Hallal said of the second plant in an Aug. 7 statement. Outside the U.S., Scholar Rock’s application for apitegromab includes only the Catalent Indiana site, as the European Medicines Agency is holding its ruling in anticipation of the FDA’s inspection classification. The company is in discussions with European regulators to potentially use the second fill-finish facility, Hallal said on Thursday’s call. Before Scholar Rock, Regeneron had to switch manufacturing away from the ex-Catalent facility to overcome an FDA complete response letter for the prefilled syringe version of its high-dose Eylea. Regeneron has another recent FDA rejection tied to manufacturing issues at the facility for its CD20xCD3 bispecific antibody, odronextamab. The OAI may disrupt regulatory plans for other companies. Issues at the legacy Catalent plant, which Novo inherited as part of Novo Holdings’ acquisition of the CDMO in 2024, recently tripped up Incyte’s FDA bid for its PD-1 inhibitor Zynyz in first-line non-small cell lung cancer. In a statement to Fierce Pharma, Incyte confirmed that “Catalent Indiana is the primary fill-finish manufacturer” for commercial supply of Zynyz, and that it has “not experienced safety or product quality issues” for marketed products. But the company declined to comment on any plans to refile for the rejected NSCLC indication. Editor's Note: The story was edited 1:13 p.m. ET with an update to Incyte's statement.